Proceedings of the National Academy of SciencesImmunologyPeer-reviewed journal article
T Lymphocyte-Specific Deletion of SHP1 and SHP2 Promotes Activation-Induced Cell Death of CD4+ T Cells and Impairs Antitumor Response
Connor FosteriD, Jasper DuiD, Oscar J. PundeliD, Mitchell J. GeeriD, Ryan C. Ripert, Jia LiuiD, Taylor A. HeimiD, Kiyomi Y. ArakiiD, Amanda W. LundiD, Jun WangiD, Benjamin G. NeeliD
Abstract
SHP1 (PTPN6) and SHP2 (PTPN11) are closely related protein-tyrosine phosphatases (PTPs), which are autoinhibited until their SH2 domains bind paired tyrosine-phosphorylated immunoreceptor tyrosine-based inhibitory/switch motifs (ITIMs/ITSMs). These PTPs bind overlapping sets of ITIM/ITSM-bearing proteins, suggesting that they might have some redundant functions. By studying T cell-specific single and double knockout mice, we found that SHP1 and SHP2 redundantly restrain naive T cell differentiation to effector and central memory phenotypes, with SHP1 playing the dominant role. Surprisingly, loss of SHP2 alone in T cells enhanced the antitumor effects of anti-PD-1 antibodies, whereas there was no effect of SHP1 deletion. Also unexpectedly, the absence of both PTPs resulted in poorer tumor control and failure to respond to PD-1 blockade, associated with reduced frequency and activation of T cells and dendritic cells. Mechanistic studies revealed that CD4+, but not CD8+ T cells lacking SHP1 and SHP2 show increased activation-induced cell death upon anti-CD3/CD28 stimulation. Adoptive transfer of antigen-specific CD4+ T cells restored normal levels of tumor control in mice lacking both PTPs. Together, our results demonstrate that SHP1 or SHP2 is required to prevent activation-induced cell death of CD4+ T cells and is critical for tumor immunity, raising the possibility that inhibition of SHP2 might augment the therapeutic efficacy of PD-1-based immune therapy. SIGNIFICANCE STATEMENTSHP1 and SHP2 are related protein tyrosine phosphatases that associate with several of the same ITIM/ITSM-containing receptors or T cell receptor (TCR) signaling molecules. The individual roles of SHP1 and SHP2 in T cells have been reported previously, but potentially redundant functions are less well understood. Here we uncover an essential function in CD4+ T cells that is manifest only in the absence of both enzymes and is critical for the control of tumors.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 10
- FWCI
- 2.76
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2
- Inhibition of SHP-1 /2 blocks antigen cross-presentation by human macrophages and dendritic cells
Alexine Simone de Wit, Harry M. Warner, … Frans Bianchi·bioRxiv·Oct 21, 2025
- PD-1 remodels SHP2 dynamics and drives the non-catalytic inhibition of T cell activation
- T cell co-stimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
E. Hui, J. Cheung, … R. D. Vale·bioRxiv·Nov 9, 2016
- Sphingosine 1-phosphate receptor 1 inhibition induces a pro-apoptotic signaling cascade in T cells
D. Dixit, V. M. Hallisey, … S. R. Schwab·bioRxiv·Aug 21, 2023
- PTPN1/2 inhibition induces highly functional terminal effector CD8 T cells through autocrine IL-10
L. A. Perez-Quintero, A. Poirier, … M. L. Tremblay·bioRxiv·Apr 17, 2023